RSS

Sanofi

Biopharmaceutical companies, Sanofi and Ablynx, have announced the successful results of the initial tender offer period for Sanofi to acquire outstanding shares of Ablynx. more

News

The US Food and Drug Administration (FDA) has accepted priority review of the biologics licence application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC)... more

News

The marketing authorisation application (MAA) for cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma (CSCC) has been accepted for review by the European Medicines Agency (EMA). more

News

The European Medicines Agency (EMA) has accepted for review an application for an add-on maintenance treatment in certain adults and adolescents (12 years and older) with inadequately controlled moderate-to-severe asthma, Dupixent (dupilumab). more

News

The European Medicines Agency (EMA) has accepted Sanofi’s regulatory submission for sotagliflozin, a potential treatment for type 1 diabetes, for review. more

News

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. more

News

Sanofi has completed its acquisition of Bioverativ for $105 per share in cash. As a result, Bioverativ is now a fully owned subsidiary of Sanofi. more

News

The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application (sBLA) of Dupixent (dupilumab) for review, revealed joint developers of the drug, Regeneron and Sanofi. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Sanofi has requested a review by the European Medicines Agency (EMA) of its treatment for sleeping sickness, fexinidazole, which it is developing in collaboration with the Drugs for Neglected Disease initiative (DNDi). more

News

Sanofi is to acquire all outstanding ordinary shares of a biopharmaceutical company that is currently focused on the discovery and development of Nanobodies, Ablynx. more

News

A definitive acquisition agreement has been formed between Sanofi and biopharmaceutical company, Bioverativ, which will see Sanofi acquire all the outstanding shares of Bioverativ for an equity value of approximately $11.6 billion. more

News

Sanofi and Regeneron have revealed that they will accelerate and expand investment for the clinical development programmes of cemiplimab in oncology and dupilumab in type 2 allergic diseases. more

News

Two biotech companies, APEIRON and Evotec, have received the first milestone payment from Sanofi as part of the three-party immune-oncology alliance that was signed in 2015. more

News

Sanofi and RNAi therapeutics company, Alnylam Pharmaceuticals, have begun strategic restructuring of their RNAi therapeutics alliance to streamline and optimise development and commercialisation of certain products more

News

With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The US Food and Drug Administration (FDA) has approved Sanofi’s short-acting insulin (Admelog — insulin lispro injection) as a ‘follow on’ product to treat diabetes. more

News

Sanofi is requesting that health authorities update information on its dengue vaccine Dengvaxia, as a result of a new analysis of long-term clinical trial data, which found differences in vaccine performance based on prior dengue infection. more

News

Lead Pharma has achieved a third milestone under its research collaboration with Sanofi, which has triggered an undisclosed milestone payment. more

News